Can-Fite BioPharma (CANF) Enterprise Value (2013 - 2025)
Can-Fite BioPharma's (CANF) quarterly Enterprise Value came in at -$11.5 million in Q4 2025, down 46.54% YoY from -$21.6 million in Q4 2024, and down 78.9% on a QoQ basis from -$6.5 million in Q2 2025.
Can-Fite BioPharma (CANF) Enterprise Value (2013 - 2025) Analysis & Trends
Can-Fite BioPharma (CANF) has 13 years of Enterprise Value data on file, last reported at -$11.5 million in Q4 2025.
- Quarterly Enterprise Value fell 46.54% year-over-year to -$11.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$11.5 million (down 46.54% YoY) and the FY2025 annual result came in at -$11.5 million, down 46.54% from the prior year.
- Enterprise Value retreated to -$11.5 million in Q4 2025, from -$6.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$1.3 million in Q1 2023 to a low of -$18.9 million in Q4 2021.
- A 5-year average of -$6.3 million and a median of -$4.5 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2021 — Enterprise Value plunged 126.56% — and 2022, when it surged 84.2%.
- Tracing CANF's Enterprise Value over 5 years: stood at -$18.9 million in 2021, then surged by 84.2% to -$3.0 million in 2022, then sank by 43.9% to -$4.3 million in 2023, then sank by 83.43% to -$7.9 million in 2024, then slumped by 46.54% to -$11.5 million in 2025.
- The last three Enterprise Value figures came in at -$11.5 million (Q4 2025), -$6.5 million (Q2 2025), and -$7.9 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 2.12 Bn |
| 10 | Can-Fite BioPharma | 2.77 Mn | -8.78 Mn | - | -11.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -11.55 Mn |
| Jun 30, 2025 | -6.46 Mn |
| Dec 31, 2024 | -7.88 Mn |
| Jun 30, 2024 | -4.73 Mn |
| Dec 31, 2023 | -4.30 Mn |
| Sep 30, 2023 | -3.39 Mn |
| Jun 30, 2023 | -3.47 Mn |
| Mar 31, 2023 | -1.28 Mn |
| Dec 31, 2022 | -2.99 Mn |
| Sep 30, 2022 | -3.74 Mn |
| Jun 30, 2022 | -1.75 Mn |
| Mar 31, 2022 | -5.69 Mn |
| Dec 31, 2021 | -18.90 Mn |
| Sep 30, 2021 | -13.31 Mn |
| Jun 30, 2021 | -7.54 Mn |
| Mar 31, 2021 | -3.11 Mn |
| Dec 31, 2020 | -8.34 Mn |
| Sep 30, 2020 | -10.22 Mn |
| Jun 30, 2020 | -9.14 Mn |
| Dec 31, 2019 | -2.76 Mn |